Abstract
The objective of this study was to examine the effect of the antihyperglycemic agents metformin (insulin sensitizer) and glibenclamide (insulin secretory agent) on the serum level of C-reactive protein (CRP) in well-controlled type 2 diabetics with metabolic syndrome. The participants were diabetic patients being followed in the medical outpatient clinic of King Abdulaziz University Hospital. The inclusion criteria were type 2 diabetics with the metabolic syndrome, well-controlled blood glucose on metformin alone or glibenclamide alone, and exclusion of major medical illness. Patients were divided into two groups according to the antihyperglycemic agent used. CRP level was measured 4-wk apart and the mean was calculated. The following data were collected from the study groups: age, sex, body mass index (BMI), duration of diabetes, smoking history, presence of hypertension, hyperlipidemia, and mean CRP level. A total of 110 patients were studied, 65 using metformin and 45 using glibenclamide. CRP level was significantly lower in patients using metformin for blood glucose control compared with those using glibenclamide, 5.56 and 8.3 mg/L, respectively (p=0.01). A significantly higher level was observed in hypertensive and hyperlipidemic patients compared with normotensive and normolipidemic, 5.3 vs 3.2 mg/L and 7.1 vs 4.3 mg/L, respectively (p=0.02, 0.01). There was a statistically significant correlation between CRP and BMI (r=0.37) and age (r=0.36) (all p=0.01). The data showed that metformin decreases the level of circulating CRP, a marker of inflammation, more than glibenclamide.
Similar content being viewed by others
References
Kannel, W. B., D’Agostino, R. B., Wilson, P. W., Belanger, A. J., and Gagnon, D. R. (1990). Am. Heart J. 120, 672–676.
Usitupa, M. I., Niskanen, L. K., Siitonen, O., Voutilainen, E., and Pyorala, K. (1990). Circulation 82, 27–36.
Pyorala, M., Miettinen, H., Halnen, P., Laasko, M., and Pyorala, K. (2000). Arterioscl. Thromb. Vasc. Biol. 20, 538–550.
Reaven, G. M. (1988). Diabetes 37, 1595–1607.
Haffner, S. M., Valdez, R. A., Hazuda, H. P., Mitchell, B. D., Morales, P. A., and Stern, M. P. (1992). Diabetes 41, 715–722.
Haffner, S. M., D’Agostino, R., Mykkanen, L., et al. (1999). Diabetes Care 22, 562–568.
Reaven, G. M., Chen, D. I., Jeppersen, J., Maheux, P., and Krauss, R. M. (1993). J. Clin. Invest. 92, 141–146.
Jokl, R., Laimins, M., Klein, R., Lyons, T., Lopes-Virella, M., and Colwell, J. (1994). Diabetes Care 17, 818–823.
Imperatore, G., Riccardi, G., Lovine, C., Rivellse, A., and Vaccaro, O. (1998). Diabetes Care 21, 649–654.
Hak, A. E., Stehouwer, C. D., Bots, M. L., et al. (1999). Arterioscl. Thromb. Vasc. Biol. 19, 1986–1999.
Despres, J. P. and Marette, A. (1994). Curr. Opin. Lipidol. 5, 274–289.
Despres, J. P., Lamarche, B., Mauriege, P., et al. (1996). N. Engl. J. Med. 334, 952–957.
U.K. Prospective Diabetes Study. (1998). Lancet 352, 837–852.
Abraira, C., Colwell, J., Nuttall, F., et al. (1997). Arch. Intern. Med. 157, 181–188.
Chu, N. V., Caufield, M., Kong, A. P., et al. (2002). Diabetes Care 25, 542–549.
Fonseca, V. A., Reynolds, T., Hemphill, D., et al. (1998). Diabetes Complications 12, 181–186.
Tack, C. J., Smits, P., Demacker, P. N., and Stalenhoef, A. F. (1998). Diabetes Care 21, 796–799.
Minamikawa, J., Tanaka, S., Yamauchi, M., Inoue, D., and Koshiyama, H. (1998). J. Clin. Endocrinol. Metab. 83, 1818–1820.
Yudkin, J. S., Panahloo, A., Stehouwer, C., et al. (2000). Diabetologia 43(9), 1099–1106.
Baily, C. J. (1992). Diabetes Care 15, 755–772.
Groop, L. (1992). Diabetes Care 15, 737–754.
Pepys, M. B. (1996). In: Oxford textbook of medicine. Warrell, D. A. (ed.). Oxford University Press: New York.
McMillan, D. E. (1989). Metabolism 38, 1042–1046.
Pickup, J. C., Mattock, M. B., Chusney, G. D., and Burt, D. (1997). Diabetologia 40, 1286–1292.
DeFronzo, R. A. and Ferrannini, E. (1991). Diabetes Care 14, 173–194.
Kaplan, N. M. (1989). Arch. Intern. Med. 149, 1514–1520.
Alberti, K. G. M. M. and Zimmet, P. Z. (1998). Diabetes Med. 15, 539–553.
Isomaa, B. O., Lahti, K., Almgren, P., et al. (2001). Diabetes Care 24, 683–689.
Tracy, R. P., Psaty, B. M., Macy, E., et al. (1997). Arterioscl. Thromb. Vasc. Biol. 17, 2167–2176.
Haverkate, F., Thompson, S. G., Pyke, S. D. M., Gallimore, J. R., and Pepys, M. B. (1997). Lancet 349, 462–466.
Koenig, W., Frohlich, M., Sund, M., et al. (1999). Circulation 99, 237–242.
Frohlich, M., Boeing, H., Imhof, A., et al. (2000). Diabetes Care 12, 1835–1839.
Danesh, J., Muir, J., Wong, Y.-K., Ward, M., Gallimore, J. R., and Pepys, M. B. (1999). Eur. Heart J. 20, 954–959.
Kuller, L. H., Tracy, R. P., Shaten, J., Meilah, E. N. (1996). Am. Epidemiol. 144, 537–547.
Tracy, R. P., Lemaitre, R. N., Psaty, B. M., et al. (1997). Arterioscl. Thromb. Vasc. Biol. 17, 1121–1127.
Lagrand, W. K., Visser, C. A., Hermens, W. T., et al. (1999). Circulation 100, 96–102.
Cermak, J., Key, N. S., Bach, R. R., Jacob, H. S., and Vercellotti, G. M. (1993). Blood 82, 513–520.
Pepys, M. B., Rowe, I. F., and Baltz, M. L. (1985). Int. Rev. Exp. Pathol. 27, 83–111.
Mehta, R. H., Ruane, T. J., McCargar, P. A., Eagle, K. A., and Stalhandsket, E. J. (2000). Arch. Intern. Med. 8, 1301–1306.
Ceniceros, I., Gastaldo, R., Cabades, A., and Cebrian, J. (1997). Med. Clin. (Barc.) 5, 171–174.
Osztay, K. R. and Korhaza, B. (1999). Orv. Hetil. 13, 1357–1360.
Abbud, Z. A., Shindler, D. M., Wilson, A. C., and Kostis, J. B. (1995). Am. Heart J. 1, 51–58.
Demirovic, J., Blackburn, H., McGoveern, P. G., Luepker, R., Sprafka, J. M., and Gilbertson, D. (1995). Am. J. Cardiol. 16, 1096–1101.
Mendall, M. A., Strachan, D. P., Butland, B. K., et al. (2000). Eur. Heart J. 19, 1584–1590.
Eschwege, E., Richard, J. L., and Thibult, N. (1985). Horm. Metab. Res. 15, 41–46.
Hayden, C. T. and Reavn, P. D. (2000). Curr. Opin. Lipidol. 2, 519–528.
Haffner, S. M., Mykkanen, L., Stern, M. P., Valdez, R. A., Heisserman, J. A., and Bowsher, R. R. (1993). Diabetes 42, 1297–1302.
U.K. Prospective Diabetes Study (UKPDS) Group. (1998). Lancet 352, 854–865.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Akbar, D.H. Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome. Endocr 20, 215–218 (2003). https://doi.org/10.1385/ENDO:20:3:215
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/ENDO:20:3:215